Horizon Pharma acquisition to be significantly accretive, says Stifel After Horizon Pharma announced that it would acquire Vidara Therapeutics for $660M, Stifel thinks the deal will be 10% accretive in 2014 and 10%-20% accretive beyond that. The firm believes that Horizon's deal activity is favorable overall as it increases product diversity and leverages the company's promotional activities. Stifel keeps an $18 price target and Buy rating on the shares.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Horizon Pharma to host special shareholder meeting Special shareholder meeting to consider and seek shareholder approval of the acquisition of Vidara Therapeutics, will be held in Deerfield, IL on September 18 at 9 am.